Navigation Links
Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
Date:1/24/2011

s our goal of helping patients who are suffering from this disease." 

The NDA is supported by data from the two largest comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. The two fidaxomicin Phase 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a total of 1,164 adult patients. Patients with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the only FDA approved product for the treatment of CDI. In both of these studies, fidaxomicin met the primary endpoint of non-inferiority of clinical cure compared to Vancocin. Importantly, in both trials fidaxomicin was statistically superior to Vancocin in reducing recurrences of CDI and in global cure rate.

About Clostridium difficile Infection (CDI)Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
(Date:7/9/2014)... Vasectomy was associated with a small increased risk of ... lethal prostate cancer according to a new study from ... that the association remained even among men who received ... cancer cannot be explained by diagnostic bias. It is ... look at the link between vasectomy and prostate cancer. ...
(Date:7/9/2014)... of signals active in almost all types of cancer ... and may help fuel a tumour,s uncontrolled growth, new ... Research, London, identified a molecular trigger responsible for ratcheting ... cellular factory that makes the building blocks cancer cells ... TOR signalling pathway, called SREBP, controls the flow of ...
(Date:7/9/2014)... research into the metabolism of stromal support cells and ... of these cell types in the development of diseases ... conditions and cancer. That was the conclusion of a ... in the leading journal Nature . , Prof. ... wake-up call. The metabolism of cancer cells has been ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... news release is available in French . ... factors in 14 year old teens, including brain structure and ... 70% accuracy who will go on to develop binge drinking ... of conscientiousness, and other variables such as life events and ... of binge drinking. Whether or not the child had ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2
... Academy of Ophthalmology and the Texas Ophthalmological, Association Remind Parents and ... Eyewear for Youth Sports and Back-to-School ... when an errant paintball smashed into his left eye and sent ... "I remember being very dizzy and I couldn,t stop vomiting," ...
... WASHINGTON, Sept. 1 /PRNewswire-USNewswire/-- Service Employees,International Union (SEIU) ... RN, issued the following statement regarding the work,being ... country in anticipation of,the health impacts of Hurricane ... the Gulf Coast, leaders of the Nurse,Alliance of ...
... Israel, Aug. 31 Elbit Imaging Ltd.,(Nasdaq: EMITF ... for the,second quarter of 2008., Profit for the ... US$ 16.7 million) of which profit of NIS 15.8 ... holders of,the Company and NIS 40.3 million (approximately US$ ...
... WASHINGTON, Aug. 31 As mandatory evacuations are ... is starting to receive,evacuees in shelters throughout the Gulf ... states: Alabama, Mississippi, Louisiana and Texas.,Everyone in the path ... officials,and heed evacuation orders when instructed to do so; ...
... Spanish . , The brain is the ... a complex, orchestrated manner that is related to the activation ... cognitive and emotional processes. It is the brain which finally ... stressful for us, and which regulates the stress responses that ...
... HAMILTON August 31, 2008 -- An international study ... medication used to lower blood pressure, reduced the outcome ... who are unable to tolerate a widely available and ... Teo, professors in the Michael G. DeGroote School of ...
Cached Medicine News:Health News:Keep Eyes Safely On The Ball 2Health News:Keep Eyes Safely On The Ball 3Health News:Nurse Alliance of SEIU Healthcare Mobilizing RNs and Medical Supplies to Gulf Coast Areas in Advance of Hurricane Gustav 2Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 13Health News:Elbit Imaging Ltd. Announces Second Quarter Results for 2008 14Health News:American Red Cross Relief Efforts Underway for Gustav 2Health News:Neurogenesis in the adult brain: The association with stress and depression 2Health News:Neurogenesis in the adult brain: The association with stress and depression 3Health News:Neurogenesis in the adult brain: The association with stress and depression 4Health News:Neurogenesis in the adult brain: The association with stress and depression 5Health News:Global study shows telmisartan reduces outcome of cardiovascular death, heart attack or stroke 2
BD Vacutainer Citrate Tubes with 3.2% buffered sodium citrate solution are used for routine coagulation studies....
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
... tubes are available in two ... contains a clotting activator and ... where serum is required for ... tube is suitable where the ...
Inquire...
Medicine Products: